Kringle Pharma, Inc. announced that KRINGLE and Keio University jointly filed a patent application regarding the treatment of chronic spinal cord injury. The filing is to claim a priority based on the previous patent application filed with Keio University on March 11, 2022, providing broad and comprehensive patent protection on therapeutic agents for chronic spinal cord injury.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
839 JPY | +5.93% | +2.07% | +11.57% |
1st Jan change | Capi. | |
---|---|---|
+11.57% | 34.23M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- 4884 Stock
- News Kringle Pharma, Inc.
- Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury